Biomedical subjects
Publications and source records attributed to T Fredriksson.
A 16-year-old girl with dark-brown coalescing papules symmetrically localized to the cheeks, is reported. The diagnosis may be consistent with the criteria for confluent and reticulate papillomatosis (Gougerot-Carteaud). The association between this disease and Pityrosporum orbiculare is discussed.
We have investigated the incidence of the lipophilic fungi Pityrosporum orbiculare and P. ovale on clinically normal skin in newborn children and in children at the age of 6 months, 1 year, 5 years, 10 years, and 15 years. P. orbiculare was absent in children of less than 5 years of age. It was present in the highest incidence (93%) in the 15-year-old children, about the same frequency as in adults. The colonization starts during the period when the sebaceous glands become active. P. ovale could not be cultured and this may depend on geographical variations in the distribution of these yeasts.
The effect of zinc pyrithione 1 percent, incorporated in a shampoo, has been tested in an open trial of twenty patients with tinea versicolor. The period of treatment was two weeks, and eighteen patients returned for follow-up visits two weeks after the last day of treatment. All of these patients were cured of tinea versicolor clinically, under Wood's light, and microscopically. No side effects were noticed in any of the patients and the patients found the shampoo cosmetically acceptable.
The antimycotic activity of ethane-1,2-diol, propane-1,2-diol, butane-1,3-diol, pentane-1,5-diol, and hexane-2,5-diol in vitro against Pityrosporum orbiculare, Candida albicans, Trichophyton rubrum, T. mentagrophytes var. interdigitale and Epidermophyton floccosum was studied. Ethane-1,2-diol had the lowest activity (MIC of 40-100 g 1(-1)), and hexane-2,5-diol the highest activity (MIC of 10-40 g 1(-1)). Among, the higher diols there can be both effective antifungal agents and substances with a lower risk of allergic and irritative skin reactions than propane-1,2-diol.
Ro 10-9359 is a retinoic acid derivative, selected for study because of a better tolerance than retinoic acid, shown in animal experiments. Earlier clinical experience has proved Ro 10-9359 to be an extremely potent antipsoriatic drug. The well-known association between psoriasis and pustulosis palmoplantaris was a motivation to evaluate Ro 10-9359 also in the last-mentioned disease, which is notoriously known to be resistant to treatment. In this study 30 patients were given either 75 mg/day of Ro 10-9359 or 200 mg twice every week according to a randomized pattern. All patients had suffered from the disease for at least 2 years without any spontaneous remission during the year preceding the trial. After a treatment period of about 2 weeks with Ro 10-9359 hyperkeratotic scales had usually disappeared, and 2 weeks later there were in general significantly less pustular lesions. The treatment continued for 8 weeks, and at this time the average reduction of the number of pustules was 80%. The daily dosage seemed to give better results and was also better tolerated than was the twice-weekly dosage. Side effects were common, but generally mild. On average, the remission lasted 1 month after cessation of therapy.
In a double-blind, randomized study, 0.05% clobetasone butyrate cream was found to be as effective as 0.1% betamethasone valerate in the treatment of 48 patients with atopic or contact dermatitis, after 2 weeks as well as after 4 weeks of treatment. Side-effects with both drugs were rare and mild.
This is a retrospective study of 232 patients, and a prospective survey of 48 patients, regarding susceptibility factors in tinea versicolor, particularly in association with seborrheic dermatitis. In both surveys, a higher (10.4%) than expected (3.8%) percentage of association with seborrheic dermatitis was found.
Ro 10-9359 is a retinoic acid derivative, selected for study because of a better tolerance than retinoic acid, shown in animal experiments. Doses of 25 mg b.i.d., 25 mg t.i.d. and 50 mg b.i.d. were administered orally to 27 patients suffering from severe chronic generalized psoriasis. The clinical efficacy was evaluated by means of a new index, psoriasis area and severity index (PASI) based on severity and area of psoriatic lesions. At doses of 25 mg t.i.d. or 50 mg b.i.d. Ro 10--9359 proved to be an extremely potent antipsoriatic drug. A more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment. This good effect lasted about 5 weeks after treatment. Side effects were frequent, but mostly mild and completely reversible after termination of treatment.
42 patients with acne vulgaris, clinically resistant to prior therapy with tetracyclines, were evaluated after therapy with sulphamethoxazole-trimethoprim (400 + 80 mg) twice daily. Initially and after 6, 12 and 18 weeks of treatment in each patient the different acne lesions were counted and pus specimens from unhealed pustules were taken for bacteriological analysis. Complete remission or excellent results were obtained in 33 patients (79%) at the end of treatment despite a relative increase of Staphylococcus hominis and Propionibacterium granulosum. These species were more resistant in agar dilution test to the combination sulphamethoxazole-trimethoprim (20:1) than other isolated species.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.